Literature DB >> 15010338

Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics.

Uwe J F Tietge1, Klaus H W Böker, Michael P Manns, Matthias J Bahr.   

Abstract

Adiponectin is a novel adipocytokine negatively correlated with parameters of the metabolic syndrome, such as body mass index (BMI), body fat mass (BFM), and circulating insulin levels. Furthermore, metabolic actions directly on the liver have been described. The aim of the present study was to characterize circulating adiponectin levels, hepatic turnover, and the association of adiponectin with key parameters of hepatic as well as systemic metabolism in cirrhosis, a catabolic disease. Circulating adiponectin levels and hepatic turnover were investigated in 20 patients with advanced cirrhosis. Hepatic hemodynamics [portal pressure, liver blood flow, hepatic vascular resistance, indocyanine green (ICG) half-life], body composition, resting energy expenditure, hepatic free fatty acids (FFA) and glucose turnover, and circulating levels of hormones (catecholamines, insulin, glucagon) and proinflammatory cytokines (IL-1beta, TNF-alpha, IL-6) were also assessed. Circulating adiponectin increased dependently on the clinical stage in cirrhosis compared with controls (15.2 +/- 1.7 vs. 8.2 +/- 1.1 microg/ml, respectively, P < 0.01), whereas hepatic extraction decreased. Adiponectin was negatively correlated with parameters of hepatic protein synthesis (prothrombin time: r = -0.62, P = 0.003; albumin: r = -0.72, P < 0.001) but not with transaminases or parameters of lipid metabolism. In addition, circulating adiponectin increased with portal pressure (r = 0.67, P = 0.003), hepatic vascular resistance (r = 0.60, P = 0.008), and effective hepatic blood flow (ICG half-life: r = 0.69, P = 0.001). Adiponectin in cirrhosis was not correlated with BMI, BFM, parameters of energy metabolism, insulin levels, hepatic FFA and glucose turnover, and circulating proinflammatory cytokines. These results demonstrate that 1) adiponectin plasma levels in cirrhosis are significantly elevated, 2) the liver is a major source of adiponectin extraction, and 3) adiponectin levels in cirrhosis do not correlate with parameters of body composition or metabolism but exclusively with reduced liver function and altered hepatic hemodynamics.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15010338     DOI: 10.1152/ajpendo.00494.2003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  39 in total

1.  Study of adiponectin in chronic liver disease and cholestasis.

Authors:  Tary A Salman; Naglaa Allam; Gasser I Azab; Ahmed A Shaarawy; Mona M Hassouna; Omkolsoum M El-Haddad
Journal:  Hepatol Int       Date:  2010-10-09       Impact factor: 6.047

Review 2.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Adiponectin, a key adipokine in obesity related liver diseases.

Authors:  Christa Buechler; Josef Wanninger; Markus Neumeier
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

4.  The association between adiponectin (+45T/G) and adiponectin receptor-2 (+795G/A) single nucleotide polymorphisms with cirrhosis in Iranian population.

Authors:  Fatemeh Namvaran; Parvaneh Rahimi-Moghaddam; Negar Azarpira; Saman Nikeghbalian
Journal:  Mol Biol Rep       Date:  2011-06-25       Impact factor: 2.316

5.  Adipocytokines and liver fibrosis stages in patients with chronic hepatitis B virus infection.

Authors:  Ching-Sheng Hsu; Wei-Liang Liu; You-Chen Chao; Hans Hsienhong Lin; Tai-Chung Tseng; Chia-Chi Wang; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2015-03-12       Impact factor: 6.047

6.  Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis.

Authors:  Maria Kalafateli; Christos Triantos; Emmanuel Tsochatzis; Marina Michalaki; Efstratios Koutroumpakis; Konstantinos Thomopoulos; Venetsanea Kyriazopoulou; Eleni Jelastopulu; Andrew Burroughs; Chryssoula Lambropoulou-Karatza; Vasiliki Nikolopoulou
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

7.  Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus.

Authors:  Fatemeh Namvaran; Parvaneh Rahimi-Moghaddam; Negar Azarpira; Mohammad Hosein Dabbaghmanesh
Journal:  Mol Biol Rep       Date:  2011-12-21       Impact factor: 2.316

Review 8.  Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease.

Authors:  Nikolaos K Gatselis; George Ntaios; Konstantinos Makaritsis; George N Dalekos
Journal:  Clin Exp Med       Date:  2013-01-05       Impact factor: 3.984

Review 9.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

10.  Quantitative loci regulating plasma levels of gamma glutamyl transferase and albumin and their genetic correlations with cardiovascular risk factors.

Authors:  Tanushree Bose; V Saroja Voruganti; M Elizabeth Tejero; J Michael Proffitt; Laura A Cox; John L VandeBerg; Michael C Mahaney; Jeffrey Rogers; Jeanne H Freeland-Graves; Shelley A Cole; Anthony G Comuzzie
Journal:  Exp Biol Med (Maywood)       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.